Implications of FDA Granting Priority Review to AZ's Ravulizumab

The FDA has accepted and granted priority review to the supplemental Biologics License Application from AstraZeneca Rare Disease for ravulizumab as a treatment for adults with immunoglobulin A nephropathy.1 This rare inflammatory kidney disease affects more than 217,000 people in the US. If approved, ravulizumab would become the first C5 complement inhibitor indicated for this condition. For a disease in which patients frequently progress to end-stage kidney disease despite currently available treatments, the designation signals that regulators view the unmet need as substantial.

Immunoglobulin A nephropathy develops when abnormal immunoglobulin A protein forms immune complexes that deposit in the kidneys, activating the complement system and driving terminal complement-mediated inflammation.1 This cascade damages the glomeruli, the kidney's filtering structures, and over time impairs kidney function in ways that can culminate in kidney failure. Approximately half of patients with elevated urinary protein or reduced kidney function face that outcome within a decade of diagnosis.

The supplemental application is supported by a prespecified interim analysis from the Phase III I CAN trial, a global, randomized, double-blind, placebo-controlled study enrolling roughly 510 participants across 28 countries.1 Participants were randomized to receive ravulizumab or placebo intravenously over 106 weeks, with stable standard-of-care treatment maintained throughout.

At the 34-week interim mark, ravulizumab produced a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline, compared with 5.6% in the placebo group, a placebo-adjusted treatment effect of 43.4% that was highly statistically significant.1 The proteinuria reduction appeared as early as week 10 and was sustained through week 34, with consistent results observed across patient subgroups representing varied demographic and clinical profiles. The safety profile aligned with ravulizumab's established record across its other approved indications, with no new concerns identified. The trial's second primary endpoint, change in estimated glomerular filtration rate at week 106, will be assessed in the final analysis.

What Are the Implications for Pharmaceutical Development and Manufacturing?

Ravulizumab is already approved across four indications, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. A potential fifth approval would require AstraZeneca and its manufacturing partners to anticipate incremental demand for a large-molecule biologic administered on an every-eight-week intravenous dosing schedule.1

From a development standpoint, the I CAN trial exemplifies the growing industry practice of designing studies with dual primary endpoints and prespecified interim analyses, a regulatory strategy that can accelerate approval timelines while maintaining analytical rigor.1 Sponsors working on complement pathway therapies or other biologics for rare kidney diseases will likely study this filing as a procedural model.

The complement pathway continues to prove a productive target for drug development, and ravulizumab's expansion into immunoglobulin A nephropathy reinforces the commercial and scientific rationale for sustained investment in complement biology platforms.1

How Does Ravulizumab's Complement Pathway Progress Compare with that of Other Targeted Approvals?

The complement pathway is not the only biological mechanism drawing renewed regulatory attention.2 On June 12, the FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted treatment for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The approval, based on Phase III CAPItello-281 trial data showing a 19% reduction in risk of radiographic disease progression or death, marks capivasertib's entry into a second tumor type. Both approvals reflect an accelerating industry shift toward biomarker-defined patient populations and pathway-specific therapeutic strategies.

References

1. AstraZeneca PLC. Ultomiris granted priority review in the US as treatment for adults with immunoglobulin A nephropathy. Press Release. June 15, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-granted-priority-review-in-the-us-as-treatment-for-adults-with-immunoglobulin-a-nephropathy.html
2. AstraZeneca PLC. Truqap approved in US for prostate cancer. Press Release. June 11, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-cancer.html